AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable
AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.
You may also be interested in...
The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.
Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.